Tuesday, 06 December 2016 09:00 AM
CARLSBAD, CA / ACCESSWIRE / December 6, 2016 / Isodiol, the Southern California-based cannabinoid innovator, is sponsoring a presentation that explains cannabis-based therapeutic industry advances at the American Academy of Anti-Aging Medicine (A4M)'s global congress in Las Vegas, Nevada on Friday, December 9th at 5:30 p.m. The A4M was established in 1992 and represents 26,000 physicians and scientists from 120 countries worldwide. The presentation titled "IsoDerm CBD: Novel Non-Systemic Cannabinoid Therapy" will be presented by Dr. Ronald Aung-Din explaining:
- Novel, proprietary delivery of cannabinoids using direct nerve connections of skin to central nervous system (CNS), without blood flow requirements and restrictions of blood-brain barrier
- Therapeutic benefits as cannabinoid receptors in skin free nerve-endings are activated by topical applications at strategic locations
- Therapeutic benefits observed in less than 10-15 minutes without systemic side effects or drug interactions
- Uses of universally available, unregulated hemp-derived cannabainoids
- Clinically observed to benefit a wide range of neurologic, psychiatric, and pain conditions; including: spasticity, muscle spasms, tremor, headache, neuropathies and neuropathic pain, seizures, anxiety, attentional and focus problems, cognitive blunting, social isolation, impulsivity, agitation, insomnia, fibromyalgia symptoms, nervous tics, and others
- May be purchased OTC without prescription; but should be used with medical supervision, if prior traditional medications are to be tapered as result of clinical improvement with Direct Effects Therapy
- Patents filed with USPTO and foreign patent offices; seven separate patents granted related to Direct Effects Therapy
About Dr. Ronald Aung-Din
Dr. Ronald Aung-Din has practiced General Neurology & Neuro-Psychiatry in Sarasota, FL over 25 years. He is board-certified by American Board of Psychiatry & Neurology and member, American Academy of Neurology.
After studies in Mechanical and Environmental Engineering at Bucknell (Lewisburg, PA) and Cornell (Ithaca, NY) Universities, he worked for a period in industry as supervising engineer. He then attended Columbia University in New York City for Premedical studies, followed by Medical School at University of Texas Southwestern Medical School, Dallas, TX. Residencies in Neurology and Neurosurgery were at University of Florida, Gainesville, FL. Additional studies included a Medical Student Fellowship in Cardiology at Radcliffe Infirmary, Oxford and Clinical Neurology Postgraduate Fellowship at National Hospital for Nervous Disease, Queen Square, London, UK.
Through his affiliation with Lovelace Scientific Resources, Inc., Albuquerque, NM and his own clinical practice, he has participated in over 60 pharmaceutical industry-sponsored clinical trials. He currently functions as Principal Investigator in a number of ongoing drug research studies in MS, epilepsy, pain, Parkinson's disease, and other neurological diseases.
Dr. Aung-Din is also active in treating varied neurological and psychiatric conditions using delivery of CNS-active drugs with Direct Effects topical delivery, a technology developed by him for which 7 patents have to date been granted in the United States, Europe, and Australia; with others pending.
Publications using this novel therapy in migraine, Parkinson's disease, and diabetic neuropathy appeared in Drug Delivery Technology, Vol.10. No 8, p. 48, October 2010 and Drug Delivery Technology, Vol. 9. No 9, p. 44, October 2009, www.drugdeliverytech.com; and in June 2015 www.drug-dev.com: "THERAPEUTIC FOCUS - Direct Effects™ Diabetic Neuropathy Therapy: Treating Symptoms & Modifying Disease."
Direct Effects topical drug delivery is unique in that therapeutic effect occurs through cutaneous free-nerve endings with direct afferent connections to CNS. As such, general circulation and blood-brain-barrier are bypassed, with avoidance of systemic side effects and drug interactions. AfGin Pharma, LLC was founded by Dr. Aung-Din in 2009 to advance this unique technology and its goal of "Enhanced Neuro-Therapeutics through Direct Effects Topical Technology;" website: afginpharma.com.
Isodiol is exhibiting (booth# 8027) during the A4M's 24th Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine December 9th – 11th held at the Venetian located at 3355 Las Vegas Blvd. S., Las Vegas, NV 89109.
For information on the conference, visit www.A4M.com
About Isodiol:
Isodiol and its team of collaborators are a group of companies that together, grow & harvest hemp on an industrial scale, and then process it to extract the non-psychoactive cannabidiol CBD to the highest available purity for worldwide distribution. By utilizing one of the world's largest hemp farms, Isodiol and its partners are the choice for industrial volumes of high-grade, non-psychoactive CBD. Pharmaceutical, nutraceutical and cosmetic companies worldwide have gained market share due to our products. For more information, visit www.Isodiol.com. To follow Isodiol online, visit the Company's website at http://www.isodiol.com, Facebook, Instagram, and Twitter.
LEGAL DISCLOSURE
Isodiol does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). Cannabidiol is a natural element of industrial hemp. Isodiol's products are not intended to cure, mitigate or diagnose disease states.
Media Contact: Denise Mahaffey 760.908.6565 [email protected]
SOURCE: Isodiol